Skip to content

A clinical trial to study effectiveness and safety Mool Healths customized Gut Health Regimen in Irritable Bowel Syndrome

Evaluation of the Effectiveness and Safety of Mool Healths customized Gut Health Regimen in Irritable Bowel Syndrome - A Double-Blind Study - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/03/083655
Enrollment
38
Registered
2025-03-28
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K929- Disease of digestive system, unspecified

Interventions

Intervention1: 1. Ayurvedic supplement for mild Constipation (Avipattikar Churna, Triphala Churna) 2. Ayurvedic supplement for severe Constipation (natural laxative) 3. Ayurvedic supplement for improv

Sponsors

Tatvartha Health Private Limited,
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Males/females of age of 18 years and 65 years. 2.Persistent symptoms of abdominal pain, bloating, and altered bowel habits for at least 3 months prior to screening. 3.Participants who can and are willing to provide written Informed Consent. 4.Participants who are willing to follow dietary instructions. 5.Female participant of child-bearing potential must agree to practice a medically acceptable method of birth control during the study period. 6.Participants must agree not to undergo any other type of treatment or procedure for his/her current problem during the study.

Exclusion criteria

Exclusion criteria: 1.Participant with a known history of allergy to any of the ingredients of the nutraceutical regimen or history or presence of multiple severe allergies. 2.Female participant who is pregnant or planning pregnancy during the study period or breastfeeding. 3.Participant with history of significant surgeries affecting gastrointestinal function within the past 6 months 4.Participant with active gastrointestinal ulcers or a recent history of peptic or duodenal ulcers. 5.Participant with hepatic disorders or fatty liver disease. 6.Participant with skin disorders related to immune function, such as seborrheic dermatitis 7.Participant with history of previous treatment with test product/s within the past 4 months.

Design outcomes

Primary

MeasureTime frame
To assess the change in IBS symptoms, score as measured by the PI Adapted IBS-SSS Score and Bristol Stool ChartTimepoint: From baseline to Day 84.

Secondary

MeasureTime frame
1. Evaluate change in IBS symptoms as measured by the PI adapted IBS-SSS Score and Bristol Stool Chart. 2. Assess changes in quality of life by evaluating stress levels and sleep patterns as recorded in PI adapted IBS-SSS Score. 3. Assess the Adverse Events profile reported with Mool Healths customized Gut Health Regimen in participants with IBS. Timepoint: From baseline to week 3, 6, 9, and 12 time points.

Countries

India

Contacts

Public ContactSyed Atif Hussain

Strider Lifesciences Pvt Ltd

syedatif.hussain@striderdct.com09901610610

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026